There have been no new clinical antibiotics developed for Gram-negative bacteria since the discovery of the quinolones in the 1960-1970s. Crucially, widespread antimicrobial resistance is predicted to cause more deaths than cancer worldwide by 2050 (O’Neill 2014, UK Government Report). The development of novel antibiotics is urgently required to tackle emerging Gram-negative infectious diseases. The Moore group is developing new ideas to address this major challenge (in review).
Mechanisms of antimicrobial resistance